welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy program. Sarepta previously announced on July 25, 2018, that the FDA placed the program on clinical hold due to the presence of trace amounts of DNA fragment in research-grade third-party supplied plasmid in a manufacturing lot. In response, and in collaboration with Nationwide Children’s Hospital, an action plan was developed and submitted to the FDA, including an audit of the plasmid supplier and a commitment to use GMP-s plasmid for all future production lots.
rareRelated
-
Pharmacokinetic Properties of Chronic Administration of Eteplirsen in the Treatment of Boys with Duchenne Muscular D...Objective: The objective of this analys...
-
The Gene-Edited Babies And CRISPR-Cas9 Controversy, ExplainedOutrage continues to grow over the news ...
-
New therapeutic approaches: I.9 Treatment of Duchenne muscular dystrophy: current efforts, bottlenecks and future pr...In the last decade a number of therapeut...
-
DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UKWith Duchenne muscular dystrophy (DMD) c...
-
Research of Biomarkers in Duchenne Muscular Dystrophy PatientsThe purpose of this study is to identify...
-
Peak Cough Flow and Cough Clearance in Patients With Muscular DystrophyThis study is to determine whether physi...
-
Local boy with Duchenne muscular dystrophy begins promising gene-targeted therapySeven-year-old Wyatt Hubbard was a bit t...
